Chandra Bhagat Pharma Share Price
Sector: Biotechnology & Drugs
58.00 -0.50 (-0.85%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
52.10
Today’s High
58.00
52 Week Low
46.15
52 Week High
110.75
Key Metrics
- Market Cap (In Cr) 43.76
- Beta 0.3
- Div. Yield (%) 0
- P/B 1.47
- TTM P/E 45.9
- Peg Ratio 19.84
- Sector P/E 23.59
- D/E 0.01
- Open Price 52.1
- Prev Close 58.5
Chandra Bhagat Pharma Analysis
Price Analysis
-
1 Week4.46%
-
3 Months-6.55%
-
6 Month-11.63%
-
YTD-10.92%
-
1 Year-41.5%
Risk Meter
- 90% Low risk
- 90% Moderate risk
- 90% Balanced Risk
- 90% High risk
- 90% Extreme risk
Chandra Bhagat Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 86.72
- Selling/ General/ Admin Expenses Total
- 2.51
- Depreciation/ Amortization
- 0.95
- Other Operating Expenses Total
- 12.38
- Total Operating Expense
- 89.13
- Operating Income
- -2.41
- Net Income Before Taxes
- 1.17
- Net Income
- 0.86
- Diluted Normalized EPS
- 1.14
- Period
- 2025
- Total Assets
- 101.53
- Total Liabilities
- 71.56
- Total Equity
- 29.97
- Tangible Book Valueper Share Common Eq
- 39.72
- Period
- 2025
- Cashfrom Operating Activities
- -5.71
- Cashfrom Investing Activities
- -0.78
- Cashfrom Financing Activities
- 2.19
- Net Changein Cash
- -4.3
- Period
- 2024
- Total Revenue
- 221.37
- Selling/ General/ Admin Expenses Total
- 2.66
- Depreciation/ Amortization
- 0.49
- Other Operating Expenses Total
- 17.72
- Total Operating Expense
- 229.06
- Operating Income
- -7.68
- Net Income Before Taxes
- 2.26
- Net Income
- 1.53
- Diluted Normalized EPS
- 2.1
- Period
- 2024
- Total Assets
- 101.8
- Total Liabilities
- 72.8
- Total Equity
- 29.01
- Tangible Book Valueper Share Common Eq
- 38.45
- Period
- 2024
- Cashfrom Operating Activities
- 6.18
- Cashfrom Investing Activities
- -1.85
- Cashfrom Financing Activities
- -5.8
- Net Changein Cash
- -1.48
- Period
- 2023
- Total Revenue
- 119.67
- Selling/ General/ Admin Expenses Total
- 1.56
- Depreciation/ Amortization
- 0.11
- Other Operating Expenses Total
- 8.21
- Total Operating Expense
- 116.62
- Operating Income
- 3.06
- Net Income Before Taxes
- 1.16
- Net Income
- 0.91
- Diluted Normalized EPS
- 1.29
- Period
- 2023
- Total Assets
- 60.58
- Total Liabilities
- 33.1
- Total Equity
- 27.48
- Tangible Book Valueper Share Common Eq
- 36.42
- Period
- 2023
- Cashfrom Operating Activities
- 5.26
- Cashfrom Investing Activities
- -0.06
- Cashfrom Financing Activities
- -4.45
- Net Changein Cash
- 0.76
- Period
- 2022
- Total Revenue
- 94.08
- Selling/ General/ Admin Expenses Total
- 1.7
- Depreciation/ Amortization
- 0.04
- Other Operating Expenses Total
- 8.34
- Total Operating Expense
- 91.52
- Operating Income
- 2.55
- Net Income Before Taxes
- 1.1
- Net Income
- 0.8
- Diluted Normalized EPS
- 1.14
- Period
- 2022
- Total Assets
- 72.46
- Total Liabilities
- 45.79
- Total Equity
- 26.68
- Tangible Book Valueper Share Common Eq
- 35.35
- Period
- 2022
- Cashfrom Operating Activities
- 12.46
- Cashfrom Investing Activities
- 0.09
- Cashfrom Financing Activities
- -9.62
- Net Changein Cash
- 2.92
- Period
- 2021
- Total Revenue
- 70.7
- Selling/ General/ Admin Expenses Total
- 2.04
- Depreciation/ Amortization
- 0.03
- Other Operating Expenses Total
- 5.6
- Total Operating Expense
- 67.41
- Operating Income
- 3.29
- Net Income Before Taxes
- 0.28
- Net Income
- 0.19
- Diluted Normalized EPS
- 0.25
- Period
- 2021
- Total Assets
- 71.78
- Total Liabilities
- 45.9
- Total Equity
- 25.88
- Tangible Book Valueper Share Common Eq
- 34.3
- Period
- 2021
- Cashfrom Operating Activities
- 7.69
- Cashfrom Investing Activities
- 0.12
- Cashfrom Financing Activities
- -5.44
- Net Changein Cash
- 2.37
- Period
- 2020
- Total Revenue
- 93.98
- Selling/ General/ Admin Expenses Total
- 2.44
- Depreciation/ Amortization
- 0.03
- Other Operating Expenses Total
- 2.67
- Total Operating Expense
- 90.94
- Operating Income
- 3.04
- Net Income Before Taxes
- 0.42
- Net Income
- 0.31
- Diluted Normalized EPS
- 0.55
- Period
- 2020
- Total Assets
- 74.74
- Total Liabilities
- 49.05
- Total Equity
- 25.69
- Tangible Book Valueper Share Common Eq
- 34.05
- Period
- 2020
- Cashfrom Operating Activities
- -7.41
- Cashfrom Investing Activities
- 0.05
- Cashfrom Financing Activities
- 6.94
- Net Changein Cash
- -0.43
- Period
- 2019
- Total Revenue
- 106.28
- Selling/ General/ Admin Expenses Total
- 4.71
- Depreciation/ Amortization
- 0.05
- Other Operating Expenses Total
- 4.97
- Total Operating Expense
- 102.1
- Operating Income
- 4.18
- Net Income Before Taxes
- 0.89
- Net Income
- 0.69
- Diluted Normalized EPS
- 0.91
- Period
- 2019
- Total Assets
- 82.86
- Total Liabilities
- 68.41
- Total Equity
- 14.45
- Tangible Book Valueper Share Common Eq
- 19.15
- Period
- 2019
- Cashfrom Operating Activities
- 4.05
- Cashfrom Investing Activities
- -0.4
- Cashfrom Financing Activities
- -3.73
- Net Changein Cash
- -0.08
- Period
- 2025-03-31
- Total Revenue
- 21.8
- Selling/ General/ Admin Expenses Total
- 1.31
- Depreciation/ Amortization
- 0.54
- Other Operating Expenses Total
- 3.15
- Total Operating Expense
- 22.59
- Operating Income
- -0.8
- Net Income Before Taxes
- 0.55
- Net Income
- 0.17
- Diluted Normalized EPS
- 0.23
- Period
- 2025-03-31
- Total Assets
- 101.53
- Total Liabilities
- 71.56
- Total Equity
- 29.97
- Tangible Book Valueper Share Common Eq
- 39.72
- Period
- 2025-03-31
- Cashfrom Operating Activities
- -5.71
- Cashfrom Investing Activities
- -0.78
- Cashfrom Financing Activities
- 2.19
- Net Changein Cash
- -4.3
- Period
- 2024-09-30
- Total Revenue
- 64.92
- Selling/ General/ Admin Expenses Total
- 1.2
- Depreciation/ Amortization
- 0.41
- Other Operating Expenses Total
- 9.24
- Total Operating Expense
- 66.53
- Operating Income
- -1.61
- Net Income Before Taxes
- 0.61
- Net Income
- 0.68
- Diluted Normalized EPS
- 0.91
- Period
- 2024-09-30
- Total Assets
- 94.53
- Total Liabilities
- 64.84
- Total Equity
- 29.69
- Tangible Book Valueper Share Common Eq
- 39.36
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -7.28
- Cashfrom Investing Activities
- -0.67
- Cashfrom Financing Activities
- 5.36
- Net Changein Cash
- -2.59
- Period
- 2024-03-31
- Total Revenue
- 102.11
- Selling/ General/ Admin Expenses Total
- 1.64
- Depreciation/ Amortization
- 0.21
- Other Operating Expenses Total
- 11.98
- Total Operating Expense
- 104.36
- Operating Income
- -2.25
- Net Income Before Taxes
- 1.34
- Net Income
- 0.9
- Diluted Normalized EPS
- 1.19
- Period
- 2024-03-31
- Total Assets
- 101.8
- Total Liabilities
- 72.8
- Total Equity
- 29.01
- Tangible Book Valueper Share Common Eq
- 38.45
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 6.18
- Cashfrom Investing Activities
- -1.85
- Cashfrom Financing Activities
- -5.8
- Net Changein Cash
- -1.48
- Period
- 2023-09-30
- Total Revenue
- 119.26
- Selling/ General/ Admin Expenses Total
- 1.02
- Depreciation/ Amortization
- 0.43
- Other Operating Expenses Total
- 5.74
- Total Operating Expense
- 124.69
- Operating Income
- -5.43
- Net Income Before Taxes
- 0.92
- Net Income
- 0.63
- Diluted Normalized EPS
- 0.84
- Period
- 2023-09-30
- Total Assets
- 59.65
- Total Liabilities
- 31.54
- Total Equity
- 28.11
- Tangible Book Valueper Share Common Eq
- 37.26
- Period
- 2023-09-30
- Cashfrom Operating Activities
- -1.41
- Cashfrom Investing Activities
- -1.65
- Cashfrom Financing Activities
- -2.54
- Net Changein Cash
- -5.6
- Period
- 2023-03-31
- Total Revenue
- 75.4
- Selling/ General/ Admin Expenses Total
- 0.81
- Depreciation/ Amortization
- 0.22
- Other Operating Expenses Total
- 5.77
- Total Operating Expense
- 73.32
- Operating Income
- 2.08
- Net Income Before Taxes
- 0.62
- Net Income
- 0.54
- Diluted Normalized EPS
- 0.71
- Period
- 2023-03-31
- Total Assets
- 60.58
- Total Liabilities
- 33.1
- Total Equity
- 27.48
- Tangible Book Valueper Share Common Eq
- 36.42
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 5.26
- Cashfrom Investing Activities
- -0.06
- Cashfrom Financing Activities
- -4.45
- Net Changein Cash
- 0.76
- Period
- 2022-09-30
- Total Revenue
- 44.27
- Selling/ General/ Admin Expenses Total
- 0.75
- Depreciation/ Amortization
- 0.05
- Other Operating Expenses Total
- 2.44
- Total Operating Expense
- 43.3
- Operating Income
- 0.98
- Net Income Before Taxes
- 0.54
- Net Income
- 0.37
- Diluted Normalized EPS
- 0.49
- Period
- 2022-09-30
- Total Assets
- 71.77
- Total Liabilities
- 44.73
- Total Equity
- 27.04
- Tangible Book Valueper Share Common Eq
- 35.84
- Period
- 2022-09-30
- Cashfrom Operating Activities
- -4
- Cashfrom Investing Activities
- -0.22
- Cashfrom Financing Activities
- -0.51
- Net Changein Cash
- -4.73
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Chandra Bhagat Pharma Technical
Moving Average
SMA
- 5 Day58.09
- 10 Day57.6
- 20 Day56.33
- 50 Day61.37
- 100 Day0
- 300 Day0
Chandra Bhagat Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sandu Pharmaceuticals
- 51.03
- -0.96
- -1.85
- 69.5
- 43.75
- 49.2
- Roopa Industries
- 59.88
- 0.87
- 1.47
- 114.9
- 47.26
- 47.1
- Chandra Bhagat Pharma
- 58
- -0.5
- -0.85
- 110.75
- 46.15
- 43.76
- Gujarat Terce Laboratories
- 55.59
- -2.16
- -3.74
- 94.9
- 44.52
- 41.56
- Ang Lifesciences India
- 29.98
- -0.02
- -0.07
- 62.75
- 21.03
- 39.14
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sandu Pharmaceuticals
- 32.49
- 1.2
- 3.89
- 2.23
- Roopa Industries
- 22.96
- 2.65
- 9.8
- 1.91
- Chandra Bhagat Pharma
- 51.32
- 1.47
- 3.13
- 0.72
- Gujarat Terce Laboratories
- -
- 6.62
- -10.41
- -1.93
- Ang Lifesciences India
- -
- 0.61
- 7.28
- 2.53
Chandra Bhagat Pharma Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-May-25
- Audited Results
- 13-Nov-24
- Half Yearly Results
- 30-May-24
- Audited Results
- 09-Nov-23
- Half Yearly Results
- 22-May-23
- Audited Results
- 14-Nov-22
- Half Yearly Results
- 26-May-22
- Audited Results
- 13-Nov-21
- Half Yearly Results
- 29-Jun-21
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 30-Sept-24
- 10-Sept-24
- AGM
- 30-Sept-23
- 06-Sept-23
- AGM



